We are pleased to announce the signing of a Service Agreement with adivo covering the generation of a production cell line for their canine therapeutic mAb candidate.

For the project, FyoniBio will use its versatile CHOnamite® cell line development platform, that integrates a high-performance Transposase technology and comprises various host
cell lines to select the most suitable cell line to produce adivo’s canine mAb format at the highest quality and yield.

Read press release